These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32157052)

  • 1. [Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer].
    Kagawa Y; Hata T; Naito A; Kawai K; Sakamoto T; Murakami K; Katsura Y; Omura Y; Masuzawa T; Takeno A; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2019 Dec; 46(13):2039-2041. PubMed ID: 32157052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept: A Review in Metastatic Colorectal Cancer.
    Syed YY; McKeage K
    Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
    Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
    Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
    Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
    Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
    Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
    Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
    Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept.
    Ciombor KK; Berlin J; Chan E
    Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
    Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
    Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
    Chau I; Joulain F; Iqbal SU; Bridgewater J
    BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
    Pentheroudakis G; Kotoula V; Koliou GA; Karavasilis V; Samantas E; Aravantinos G; Kalogeropoulou L; Souglakos I; Kentepozidis N; Koumakis G; Sgouros J; Zarkavelis G; Efstratiou I; Laschos K; Petraki C; Tikas I; Poulios C; Voutsina A; Goudopoulou A; Bafaloukos D; Vrettou E; Kalogera-Fountzila A; Pectasides D; Fountzilas G
    Clin Colorectal Cancer; 2018 Dec; 17(4):e631-e637. PubMed ID: 29980490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
    Fernández Montes A; Martínez Lago N; Covela Rúa M; de la Cámara Gómez J; González Villaroel P; Méndez Méndez JC; Jorge Fernández M; Salgado Fernández M; Reboredo López M; Quintero Aldana G; Luz Pellón Augusto M; Graña Suárez B; García Gómez J
    Cancer Med; 2019 Mar; 8(3):882-889. PubMed ID: 30690930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
    Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
    Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
    Denda T; Sakai D; Hamaguchi T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Sunaga Y; Ziti-Ljajic S; Brillac C; Yoshino T
    Cancer Sci; 2019 Mar; 110(3):1032-1043. PubMed ID: 30657223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
    Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
    Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
    Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
    J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
    Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
    Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
    Riechelmann RP; Srimuninnimit V; Bordonaro R; Kavan P; Di Bartolomeo M; Maiello E; Cicin I; García-Alfonso P; Chau I; Fedyanin MY; Martos CF; Ter-Ovanesov M; Peeters M; Ko YJ; Yalcin S; Karthaus M; Aparicio J; Heinemann V; Picard P; Bury D; Drea E; Sobrero A
    Clin Colorectal Cancer; 2019 Sep; 18(3):183-191.e3. PubMed ID: 31221542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
    Pericay C; Frías C; Abad A; Lamas MJ; Echave M; Oyagüez I; Rubio M; Giménez E; Naoshy S; Joulain F
    Farm Hosp; 2014 Jul; 38(4):317-27. PubMed ID: 25137165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.